Revolution Medicines
Revolution Medicines is an innovative and dynamic organization of expert biologists, chemists, pharmacologists, clinical scientists.
Business Model:
Revenue: $0
Employees: 51-500
Rankings
Industries / Tags:
Detailed Revolution Medicines Information
Geographic Data
Address:
City: Redwood City
State: California
Zip:
Country: United States
Financial Info
Stage:
post ipo equity
Raised Last:
$265M
Raised Total:$751M
Social
Metrics
1,599,711Website Global Rank
15,900Website Monthly Traffic
Twitter Followers
Description
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines. REVOLUTION Medicines builds upon the vision of the company’s founder, Martin D. Burke, M.D., Ph.D., professor of chemistry, University of Illinois at Urbana-Champaign, and Early Career Scientist of the Howard Hughes Medical Institute, who invented a transformative method for synthesizing original compounds that are pharmaceutically optimized analogues of complex natural products. REVOLUTION Medicines has entered into an exclusive license agreement with the University of Illinois to practice and expand this technology. REVOLUTION Medicines’ approach is a rapid, standardized and powerful process for assembling simple “chemical building blocks” into refined natural product-like structures. These optimized compounds have significant potential as best-in-class drug candidates.
Contact Phone:
Contact Email:
Revolution Medicines went public on 2/12/2020 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
2/12/2020
IPO Valuation:
$967M
Ticker Symbol:
RVMD
IPO Price:
$17/share
Amount Raised:
$238M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 7/2022 | Post-IPO Equity | $264.5M | 7/2019 | Series C | 11 | $100M |
Biotechnology Value Fund Boxer Capital Casdin Capital Cormorant Capital Deerfield Capital Management Fidelity Management and Research Company Nextech Invest Schroder Adveq The Column Group Third Rock Ventures Vivo Capital Biotechnology Value Fund Boxer Capital Casdin Capital Cormorant Capital Deerfield Capital Management Fidelity Management and Research Company Nextech Invest Schroder Adveq The Column Group Third Rock Ventures Vivo Capital |
12/2016 | Series A | 2 | $25M |
The Column Group Third Rock Ventures The Column Group Third Rock Ventures |
4/2018 | Series B | 5 | $56M |
Nextech Invest Third Rock Ventures The Column Group Schroder Adveq Casdin Capital Nextech Invest |
2/2021 | Post-IPO Equity | $260.9M | 2/2015 | Series A | 1 | $45M |
Third Rock Ventures Third Rock Ventures |
|---|
| Announced Date | Name | Price |
|---|---|---|
| 10/2018 | Warp Drive Bio |
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
